浅析阿托伐他汀联合神经内分泌拮抗剂治疗慢性心力衰竭的临床效果.docVIP

精品论文 参考文献 浅析阿托伐他汀联合神经内分泌拮抗剂治疗慢性心力衰竭的临床效果 望奎县人民医院 152100 　　摘要：目的 研究分析阿托伐他汀联合神经内分泌拮抗剂治疗慢性心衰的临床效果观察。方法 此次研究的对象是选取2013年1月～2016年1月我院收治的慢性心衰患者共126例，将其临床资料进行回顾性分析，并随机分对照组与观察组，对照组患者接受神经内分泌拮抗剂治疗，观察组接受阿托伐他汀联合神经内分泌拮抗剂治疗。比较两组患者慢性心衰治疗效果及安全性。结果 观察组治疗总有效率为84.1%，明显高于对照组68.3%（Plt;0.05）。治疗后，观察组NT—proBNP明显低于对照组，射血分数、AQTd、AQTcd明显高于对照组（Plt;0.05）。治疗后观察组LVEDD、LVESD均明显低于对照组（Plt;0.05）。两组患者不良反应发生率差异无统计学意义（Pgt;0.05）。结论 阿托伐他汀联合神经内分泌拮抗治疗慢性心衰有较好的临床疗效，可改善心功能，安全可靠，值得临床推广运用。 　　关键词：阿托伐他汀；神经内分泌拮抗剂；慢性心力衰竭；临床疗效；安全性分析 　　[Abstract]Objective To study the clinical effect of Atorvastatin Combined with neuroendocrine antagonist in the treatment of chronic heart failure.The object of this research method is from January 2013 to January 2016 in our hospital 126 cases of patients with chronic heart failure，the retrospective analysis of the clinical data，were randomly divided into control group and observation group，the control group received treatment of neuroendocrine antagonist，the observation group received Atorvastatin Combined with neuroendocrine antagonist treatment.The therapeutic effect and safety of two groups of patients with chronic heart failure were compared.Results the total effective rate of the observation group was 84.1%，which was significantly higher than that of the control group 68.3%（Plt;0.05）.After treatment，the proBNP - NT of the observation group was significantly lower than that of the control group，the ejection fraction，AQTd and AQTcd were significantly higher than those in the control group（Plt;0.05）.After treatment，the LVEDD and LVESD in the observation group were significantly lower than those in the control group（Plt;0.05）.There was no significant difference in the incidence of adverse reactions between the two groups（Pgt;0.05）.Conclusion Atorvastatin Combined with neuroendocrine antagonist has better clinical efficacy in the treatment of chronic heart failure，can improve cardiac function，safe and reliable，and is worthy of clinical application. 　　[Key words]atorvastatin；neuroendo